Here's your US review and approval news for the week in brief: Nektar didn't even wait around for the US Food and Drug Administration to make a final decision on the company's novel opioid oxycodegol, as it withdrew the new drug application almost immediately after an advisory committee voted unanimously against approval.
But as one novel product application left the FDA, many others piled into the agency. GlaxoSmithKline PLC's submitted its...





